Earnings
Anika Therapeutics Reassesses Hyalafast Approval Path After FDA Rejects Submitted Clinical Data
Management cuts its commercial growth outlook but raises the floor for total revenue growth as its partner channel contributes more.
Anika Therapeutics (ANIK) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Management cuts its commercial growth outlook but raises the floor for total revenue growth as its partner channel contributes more.
Earnings
Third-quarter revenue rose 10% to $30.6 million as gross margin widened to 62%, while the FDA found Hyalofast not approvable.